Presentations to the Emergency Department Following Cannabis use—a Multi-Centre Case Series from Ten European Countries
- 505 Downloads
Cannabis is the most commonly used illicit drug in Europe, and is generally regarded as having low acute toxicity. We present the findings of the first 6 months of data collection from the Euro-DEN project on presentations related to cannabis use to further understand the acute toxicity related to the use of cannabis. Data was extracted on clinical features, treatment and outcome from the Euro-DEN minimum dataset for all cases of acute recreational drug toxicity reported 1st October 2013 to 31st March 2014 for all cannabis-related presentations. Of 2198 presentations reported by 14 of the 16 Euro-DEN centres, 356 (16.2 %) involved cannabis either alone or together with other drugs/alcohol. There were 36 that involved lone use of cannabis (1.6 % of all presentations). Of the 35 non-fatal lone cannabis presentations, the most commonly reported features were neuro-behavioural (agitation/aggression 8 (22.9 %), psychosis 7 (20.0 %), anxiety 7 (20.0 %)) and vomiting 6 (17.1 %). Most patients (25, 71.4 %) received no treatment and 30 (85.7 %) were discharged/self-discharged from the ED. There was one fatality amongst these lone-cannabis cases: an 18-year-old male collapsed with an asystolic cardiac arrest whilst smoking cannabis and suffered hypoxic brain injury related to prolonged cardiac arrest. THC was detected in a urine sample taken at ED arrival; no other drugs were detected. Lone acute cannabis toxicity was typically associated with neuro-behavioural symptoms and vomiting. Although uncommon, severe toxicity including cardiovascular toxicity and death may be under-recognised, and it is important that Emergency Physicians are aware of this.
KeywordsCannabis Acute toxicity Emergency Department Euro-DEN
With financial support from the DPIP/ISEC Programme of the European Union.
All the authors, have funding from the European Commission through the Euro-DEN project except ML and EL, whose costs were co-funded by the Swiss Centre of Applied Human Toxicology (SCAHT), and AR and KP.
- 1.European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2014: Trends and developments. 2014.Google Scholar
- 2.European Monitoring Centre for Drugs and Drug Addiction. Cannabis: last year prevalence among all adults (15-64 years) [cited 19/08/2014]. Available from: http://www.emcdda.europa.eu/countries/prevalence-maps.
- 3.European Monitoring Centre for Drugs and Drug Addiction. New development's in Europe's cannabis market 2014 updated 27/05/2014 [cited 19/08/2014]. Available from: http://www.emcdda.europa.eu/topics/pods/cannabis-markets-developments.
- 4.McGuigan M (2006) Cannabinoids. In: Flomenbaum N, Goldfrank L, Hoffman R, Howland M, Lewin N, Nelson LS (eds) Goldfrank's toxicological emergencies. McGraw-Hill, New York, pp 1212–1220Google Scholar
- 13.Hodcroft CJ, Rossiter MC, Buch AN. Cannabis-associated Myocardial Infarction in a Young Man with Normal Coronary Arteries. J Emerg Med. 2014.Google Scholar
- 16.Romero-Puche AJ, Trigueros-Ruiz N, Cerdan-Sanchez MC, Perez-Lorente F, Roldan D, Vicente-Vera T (2012) Brugada electrocardiogram pattern induced by cannabis. Revista Espanola de Cardiologia (English ed) 65(9):856–858Google Scholar
- 21.European Monitoring Centre for Drugs and Drug Addiction. Emergency health consequences of cocaine use in Europe. 2014 updated 16/05/2014 [cited 19/08/2014]. Available from: http://www.emcdda.europa.eu/topics/pods/cocaine-related-emergencies.
- 22.Heyerdahl F, Hovda KE, Giraudon I, Yates C, Dines AM, Sedefov R et al (2014) Current European data collection on emergency department presentations with acute recreational drug toxicity: Gaps and national variations.. Clin Toxicol (Phila) 52(10):1005-1012Google Scholar